ConductScience.org, home

Paper42820177PubMed

Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report.

Alghulayqah AI. Cureus, 2026.

Cite this record

ConductScience Library. Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report. Papers, record 42820177. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42820177

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nintedanib-Associated Generalized Body Swelling in a Patient With Idiopathic Pulmonary Fibrosis: A Case Report.
Journal
Cureus
Year
2026
Publication types
Case Reports, Journal Article
Revised in PubMed
2026-10-01

Source PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alghulayqah AIAbdulaziz I

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126400368Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.Respir Res2015https://conductscience.org/library/papers/26400368PubMed
222689825VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.J Exp Med2012https://conductscience.org/library/papers/22689825PubMed
337414756Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.Signal Transduct Target Ther2023https://conductscience.org/library/papers/37414756PubMed
420935110Clinical course and prediction of survival in idiopathic pulmonary fibrosis.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/20935110PubMed
534289823Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.BMC Pulm Med2021https://conductscience.org/library/papers/34289823PubMed
630841014Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis.Tuberc Respir Dis (Seoul)2019https://conductscience.org/library/papers/30841014PubMed
731016670Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.Clin Pharmacokinet2019https://conductscience.org/library/papers/31016670PubMed
817519900Mechanisms of adverse effects of anti-VEGF therapy for cancer.Br J Cancer2007https://conductscience.org/library/papers/17519900PubMed
928870253Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.J Hematol Oncol2017https://conductscience.org/library/papers/28870253PubMed
107249508A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther1981https://conductscience.org/library/papers/7249508PubMed
1112209733Severe periorbital edema secondary to STI571 (Gleevec).Cancer2002https://conductscience.org/library/papers/12209733PubMed
1236087188Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors.Target Oncol2022https://conductscience.org/library/papers/36087188PubMed
1325496490Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.Respir Res2014https://conductscience.org/library/papers/25496490PubMed
1424836310Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med2014https://conductscience.org/library/papers/24836310PubMed
1533765296Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.Drugs2021https://conductscience.org/library/papers/33765296PubMed
1621471066An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.Am J Respir Crit Care Med2011https://conductscience.org/library/papers/21471066PubMed
1725745043Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.Eur Respir J2015https://conductscience.org/library/papers/25745043PubMed
1832759374Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.Eur Respir Rev2020https://conductscience.org/library/papers/32759374PubMed
1925946646Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.Pharmacol Ther2015https://conductscience.org/library/papers/25946646PubMed
2019689244Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.Curr Drug Metab2009https://conductscience.org/library/papers/19689244PubMed

See all 23 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
SLTM79811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42820177

GET https://conductscience.org/api/papers/v1/42820177/references?page=2